<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158311</url>
  </required_header>
  <id_info>
    <org_study_id>CQVM149B2306</org_study_id>
    <secondary_id>2017-000136-34</secondary_id>
    <nct_id>NCT03158311</nct_id>
  </id_info>
  <brief_title>Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium</brief_title>
  <acronym>ARGON</acronym>
  <official_title>A Multicenter, Partially-Blinded, Randomized, 24-Week, Parallel-Group, Non-Inferiority, Open-Label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the&#xD;
      fixed-dose combination product QVM149 was non-inferior to the efficacy of the free&#xD;
      combination arm of salmeterol/ fluticasone+ tiotropium in uncontrolled moderate to severe&#xD;
      asthmatic patients.&#xD;
&#xD;
      The planned duration of treatment in this study was 24 weeks, followed up by a 7-day&#xD;
      follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study used a randomized, partially-blinded, 24-week, parallel-group, non-inferiority,&#xD;
      open-label active controlled design. The study was partially open-label. Investigators and&#xD;
      patients had knowledge of treatment allocation between QVM149 and/or comparator, however the&#xD;
      QVM149 strength allocation was masked. The global sponsor team responsible for data review&#xD;
      and analysis was blinded to all treatment allocations The study consisted of a screening&#xD;
      period of up to 1-week, run-in period of 2-weeks, randomized treatment period of 24-weeks,&#xD;
      and a follow-up period of 1-week.&#xD;
&#xD;
      At the screening visit, informed consent was obtained, and current and prohibited medications&#xD;
      were reviewed. Rescue medication was provided to all patients who met the eligibility&#xD;
      criteria and was to be used on an &quot;as needed&quot; basis throughout the study.&#xD;
&#xD;
      At the run-in visit, inclusion and exclusion criteria were reviewed and the patients were&#xD;
      supplied with open-label long acting β2-adrenergic agonist/inhaled corticosteroids (LABA/ICS)&#xD;
      salmeterol/fluticasone 50/250 μg b.i.d or 50/500 μg b.i.d to match their ICS background&#xD;
      medication dose to be stopped at randomization visit.&#xD;
&#xD;
      All patients who met the eligibility criteria were randomized to 1 of 3 treatment arms with a&#xD;
      randomization ratio of 1:1:1. The patients were stratified at randomization according to the&#xD;
      ICS dose component of background ICS/LABA (medium or high dose) and region.&#xD;
&#xD;
      Treatment period visits were scheduled every 8 weeks. The study used two doses of QVM149&#xD;
      (high dose [150/50/160 μg] and a medium dose [150/50/80 μg] o.d. delivered via Concept1&#xD;
      inhaler) and a comparator treatment (salmeterol/fluticasone 50/500 μg b.i.d. delivered via&#xD;
      Accuhaler® plus tiotropium 5 μg o.d delivered via Respimat®).&#xD;
&#xD;
      All randomized patients were contacted (by telephone) 7 days following the last dose of study&#xD;
      medication or last visit, whichever was later, for Safety Follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Actual">July 19, 2019</completion_date>
  <primary_completion_date type="Actual">July 12, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The free triple combination of salmeterol/fluticasone + tiotropium was open label, for which investigators and patients had full knowledge that the patient had been assigned free triple combination comparator treatment. Within the two QVM149 treatment arms patients, investigator staff, and persons performing the assessments, remained blind to the identity of the actual QVM149 treatment dose but had full knowledge that the patient had been assigned QVM149 as study treatment. The data analysts and sponsor team were blinded to Case Report Forms that reveal the treatment arm. Randomization data and treatment codes were kept strictly confidential until the time of unblinding, and was not accessible by anyone else involved in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional funtion, and emotional stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline, Week 8, Week 16 and Week 24</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Trough FEV1 is the mean of two FEV1 values measures taken 15 minutes (min) and 45 min prior to evening dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score</measure>
    <time_frame>Baseline, Week 16 and Week 24</time_frame>
    <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. Higher score indicates worst symptoms. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AQLQ Total Score</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional function and environmental stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Decrease From Baseline ACQ-7 ≥ 0.5</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. Higher score indicates worst symptoms. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function. Decrease of ACQ-7 score of at least 0.5 from baseline was considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Change From Baseline AQLQ ≥ 0.5</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional function and environmental stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life. An improvement of 0.5 points in AQLQ score is considered to be the minimally clinically important difference in asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline, Week 8, Week 16 and Week 24</time_frame>
    <description>FVC is the total volume of air exhaled during a expiratory maneuvre. It was assessed by performing a spirometry assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity (FEF25-75)</measure>
    <time_frame>Baseline, Week 8, Week 16 and Week 24</time_frame>
    <description>Forced expiratory flow during the mid (25 - 75%) portion of the FVC. It was assessed by performing spirometric assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1426</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>QVM149 150/50/80 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QVM149 150/50/160 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVM149</intervention_name>
    <description>Indacaterol acetate / glycopyrronium bromide / mometasone furoate</description>
    <arm_group_label>QVM149 150/50/160 μg</arm_group_label>
    <arm_group_label>QVM149 150/50/80 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol/fluticasone plus tiotropium</intervention_name>
    <description>Free triple arm of salmeterol / fluticasone plus tiotropium</description>
    <arm_group_label>Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of asthma for a period of at least 6 months prior to Visit 1&#xD;
             with current asthma severity ≥ step 4 (GINA 2017).&#xD;
&#xD;
          -  Patients who had used ICS/LABA combinations for asthma for at least 3 months and at&#xD;
             stable medium or high dose of ICS/LABA for at least 1 month prior to Visit 1.&#xD;
&#xD;
          -  Patients were required to be symptomatic at screening despite treatment with medium or&#xD;
             high stable doses of ICS/LABA as defined by ACQ-7 score ≥ 1.5 at visits 101 and 201&#xD;
             (randomization visit).&#xD;
&#xD;
          -  Patients with history of at least one severe asthma exacerbation which required&#xD;
             medical care from a physician, emergency room visit (or local equivalent structure) or&#xD;
             hospitalization in the 12 months prior to Visit 1 and required systemic corticosteroid&#xD;
             treatment for at least 3 days including physician guided self-management treatment&#xD;
             with oral corticosteroids as part of written asthma action plan.&#xD;
&#xD;
          -  Pre-bronchodilator FEV1 of &lt; 85 % of the predicted normal value for the patient after&#xD;
             withholding bronchodilators prior to spirometry at both Visit 101 and Visit 201.&#xD;
&#xD;
          -  Patients who demonstrated an increase in FEV1 of ≥ 12% and 200 ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had a smoking history of greater than 20 pack years.&#xD;
&#xD;
          -  Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).&#xD;
&#xD;
          -  Patients who had an asthma attack/exacerbation requiring systemic steroids or&#xD;
             hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening).&#xD;
&#xD;
          -  Patients treated with a LAMA for asthma within 3 months prior to Visit 1.&#xD;
&#xD;
          -  Patients who had a respiratory tract infection or clinical significant asthma&#xD;
             worsening as defined by Investigator within 4 weeks prior to Visit 1 or between Visit&#xD;
             1 and Visit 201.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berazategui</city>
        <state>Buenos Aires</state>
        <zip>1888</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1122AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1424BSF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florida</city>
        <state>Buenos Aires</state>
        <zip>B1602DQD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lanus</city>
        <state>Buenos Aires</state>
        <zip>B8000XAV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nueve de Julio</city>
        <state>Buenos Aires</state>
        <zip>B6500EZL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ranelagh, Partido De Berazate</city>
        <state>Buenos Aires</state>
        <zip>1884</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Concepcion del Uruguay</city>
        <state>Entre Rios</state>
        <zip>3260</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>La Pampa</state>
        <zip>6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <state>Nueve De Julio</state>
        <zip>B6500BWQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000AII</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000BRH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bahia Blanca</city>
        <zip>B8000JRB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1646EBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425FVH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autonoma de Bs As</city>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5501</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CBA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salta</city>
        <zip>4400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>7500692</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curico</city>
        <state>VII Region Del Maule</state>
        <zip>3341643</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110911</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava Poruba</city>
        <state>Czech Republic</state>
        <zip>708 68</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague</city>
        <state>Czech Republic</state>
        <zip>169 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teplice</city>
        <state>CZE</state>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lovosice</city>
        <zip>41002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miroslav</city>
        <zip>67172</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peine</city>
        <state>Niedersachsen</state>
        <zip>31224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geesthacht</city>
        <state>Schleswig Holstein</state>
        <zip>12502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boehlen</city>
        <zip>04564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Einbeck</city>
        <zip>37574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Furstenwalde</city>
        <zip>15517</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>D-35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Menden</city>
        <zip>58706</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mittweida</city>
        <zip>09648</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munchen</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rudersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schleswig</city>
        <zip>24837</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>546 03</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puspokladany</city>
        <state>HUN</state>
        <zip>4150</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Godollo</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komlo</city>
        <zip>7300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sellye</city>
        <zip>7960</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siofok</city>
        <zip>8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szarvas</city>
        <zip>5540</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kozhikode</city>
        <state>Kerala</state>
        <zip>673008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mohali</city>
        <state>Punjab</state>
        <zip>160 062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 045</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500 038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700 107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5266202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <zip>31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Surco</city>
        <state>Lima</state>
        <zip>33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cusco</city>
        <zip>84</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lima</city>
        <zip>1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60 823</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>109544</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>107022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bojnice</city>
        <state>Slovak Republic</state>
        <zip>972 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Humenne</city>
        <state>Slovak Republic</state>
        <zip>066 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Hradok</city>
        <state>Slovak Republic</state>
        <zip>033 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <zip>031 23</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Topolcany</city>
        <zip>95501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>01001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berea</city>
        <state>Durban</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chatsworth</city>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kempton Park</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0183</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esparraguera</city>
        <state>Barcelona</state>
        <zip>08292</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hostalets De Balenya</city>
        <state>Cataluna</state>
        <zip>08550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alzira</city>
        <state>Comunidad Valenciana</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caceres</city>
        <state>Extremadura</state>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Benalmadena</city>
        <state>Malaga</state>
        <zip>29639</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaoshiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yenisehir/Izmir</city>
        <zip>35110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <state>VNM</state>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=657</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <results_first_submitted>July 15, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QVM149</keyword>
  <keyword>Asthma</keyword>
  <keyword>Moderate Asthma</keyword>
  <keyword>Severe Asthma</keyword>
  <keyword>ICS/LABA/LAMA</keyword>
  <keyword>ICS/LABA</keyword>
  <keyword>LAMA</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03158311/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03158311/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in 166 investigative sites in 20 countries from 05 Feb 2018 to 19 Jul 2019.</recruitment_details>
      <pre_assignment_details>A total of 1917 participants were screened. A 2 week run-in phase preceded the randomized treatment phase of the study. 1821 participants entered the run-in phase. Those participants who met the inclusion criteria entered the randomized treatment phase. Participants were randomized with a randomization ratio of 1:1:1 to three treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QVM149 150/50/80 μg</title>
          <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
        </group>
        <group group_id="P2">
          <title>QVM149 150/50/160 μg</title>
          <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
        </group>
        <group group_id="P3">
          <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
          <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="474"/>
                <participants group_id="P2" count="476"/>
                <participants group_id="P3" count="476"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="474"/>
                <participants group_id="P2" count="476"/>
                <participants group_id="P3" count="475"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set (SAF)</title>
              <participants_list>
                <participants group_id="P1" count="474"/>
                <participants group_id="P2" count="476"/>
                <participants group_id="P3" count="475"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="452"/>
                <participants group_id="P2" count="460"/>
                <participants group_id="P3" count="448"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject/Guardian Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Techinical Problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>QVM149 150/50/80 μg</title>
          <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
        </group>
        <group group_id="B2">
          <title>QVM149 150/50/160 μg</title>
          <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
        </group>
        <group group_id="B3">
          <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
          <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="474"/>
            <count group_id="B2" value="476"/>
            <count group_id="B3" value="476"/>
            <count group_id="B4" value="1426"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="13.58"/>
                    <measurement group_id="B2" value="52.7" spread="13.34"/>
                    <measurement group_id="B3" value="53.1" spread="13.08"/>
                    <measurement group_id="B4" value="52.5" spread="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="306"/>
                    <measurement group_id="B2" value="289"/>
                    <measurement group_id="B3" value="307"/>
                    <measurement group_id="B4" value="902"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="391"/>
                    <measurement group_id="B4" value="1184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score</title>
        <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional funtion, and emotional stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Analysis population included FAS with evaluable AQLQ data at both timepoints. No imputation was used for missing questions or missing total AQLQ score for this analysis. The analysis was performed on observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/80 μg</title>
            <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/160 μg</title>
            <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score</title>
          <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional funtion, and emotional stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life.</description>
          <population>Analysis population included FAS with evaluable AQLQ data at both timepoints. No imputation was used for missing questions or missing total AQLQ score for this analysis. The analysis was performed on observed data only.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="453"/>
                <count group_id="O3" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.715" spread="0.070"/>
                    <measurement group_id="O2" value="0.827" spread="0.069"/>
                    <measurement group_id="O3" value="0.753" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin: 0.25 points</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value is one-sided</p_value_desc>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least Square mean (LS Mean)</param_type>
            <param_value>-0.038</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.051</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.139</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin: 0.25 points</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value is one-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.073</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.051</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.027</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Trough FEV1 is the mean of two FEV1 values measures taken 15 minutes (min) and 45 min prior to evening dose.</description>
        <time_frame>Baseline, Week 8, Week 16 and Week 24</time_frame>
        <population>Analysis population included FAS with FEV1 data at the respective visit. Number analyzed signified number of participants who were evaluable for this outcome measure at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/80 μg</title>
            <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/160 μg</title>
            <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Trough FEV1 is the mean of two FEV1 values measures taken 15 minutes (min) and 45 min prior to evening dose.</description>
          <population>Analysis population included FAS with FEV1 data at the respective visit. Number analyzed signified number of participants who were evaluable for this outcome measure at specified timepoints.</population>
          <units>Litre (L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="438"/>
                <count group_id="O3" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="395"/>
                    <count group_id="O3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.246" spread="0.020"/>
                    <measurement group_id="O2" value="0.309" spread="0.020"/>
                    <measurement group_id="O3" value="0.243" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.251" spread="0.020"/>
                    <measurement group_id="O2" value="0.319" spread="0.020"/>
                    <measurement group_id="O3" value="0.253" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="372"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.248" spread="0.021"/>
                    <measurement group_id="O2" value="0.334" spread="0.021"/>
                    <measurement group_id="O3" value="0.238" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.892</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.046</ci_lower_limit>
            <ci_upper_limit>0.052</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.945</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.050</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.066</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.713</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.096</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score</title>
        <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. Higher score indicates worst symptoms. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function.</description>
        <time_frame>Baseline, Week 16 and Week 24</time_frame>
        <population>Analysis population included FAS with ACQ-7 data at the respective visit. Number analyzed signified number of participants who were evaluable for this measure at specified timepoints. No imputation was used for missing questions or missing total ACQ-7 score for this analysis. The analysis was performed on observed data only</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/80 μg</title>
            <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/160 μg</title>
            <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score</title>
          <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. Higher score indicates worst symptoms. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function.</description>
          <population>Analysis population included FAS with ACQ-7 data at the respective visit. Number analyzed signified number of participants who were evaluable for this measure at specified timepoints. No imputation was used for missing questions or missing total ACQ-7 score for this analysis. The analysis was performed on observed data only</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="454"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="441"/>
                    <count group_id="O3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.043" spread="0.045"/>
                    <measurement group_id="O2" value="-1.098" spread="0.045"/>
                    <measurement group_id="O3" value="-1.020" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="452"/>
                    <count group_id="O3" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.080" spread="0.046"/>
                    <measurement group_id="O2" value="-1.172" spread="0.045"/>
                    <measurement group_id="O3" value="-1.048" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.308</p_value>
            <p_value_desc>P-value is one-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.113</ci_lower_limit>
            <ci_upper_limit>0.067</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>P-value is one-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.169</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.245</p_value>
            <p_value_desc>P-value is one sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.125</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is one sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.216</ci_lower_limit>
            <ci_upper_limit>-0.032</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AQLQ Total Score</title>
        <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional function and environmental stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Analysis population included FAS with evaluable AQLQ data at both timepoints. No imputation was used for missing questions or missing total AQLQ score for this analysis. The analysis was performed on observed data only</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/80 μg</title>
            <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/160 μg</title>
            <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AQLQ Total Score</title>
          <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional function and environmental stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life.</description>
          <population>Analysis population included FAS with evaluable AQLQ data at both timepoints. No imputation was used for missing questions or missing total AQLQ score for this analysis. The analysis was performed on observed data only</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="442"/>
                <count group_id="O3" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.690" spread="0.069"/>
                    <measurement group_id="O2" value="0.755" spread="0.068"/>
                    <measurement group_id="O3" value="0.673" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.719</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.079</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.097</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.179</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Decrease From Baseline ACQ-7 ≥ 0.5</title>
        <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. Higher score indicates worst symptoms. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function. Decrease of ACQ-7 score of at least 0.5 from baseline was considered clinically meaningful.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Analysis population included FAS with evaluable ACQ-7 data at both timepoints. Missing data imputation was used to perform this analysis. Subjects with missing values were imputed as non-responders (a non-responder was defined as &lt;0.5 decrease in ACQ-7 score at week 24)</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/80 μg</title>
            <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/160 μg</title>
            <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Decrease From Baseline ACQ-7 ≥ 0.5</title>
          <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. Higher score indicates worst symptoms. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function. Decrease of ACQ-7 score of at least 0.5 from baseline was considered clinically meaningful.</description>
          <population>Analysis population included FAS with evaluable ACQ-7 data at both timepoints. Missing data imputation was used to perform this analysis. Subjects with missing values were imputed as non-responders (a non-responder was defined as &lt;0.5 decrease in ACQ-7 score at week 24)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="454"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                    <measurement group_id="O2" value="387"/>
                    <measurement group_id="O3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.061</p_value>
            <p_value_desc>P-value is one sided</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression Model via Generalized estimating equations (GEE)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.227</p_value>
            <p_value_desc>P-value is one-sided</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression Model via GEE</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Change From Baseline AQLQ ≥ 0.5</title>
        <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional function and environmental stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life. An improvement of 0.5 points in AQLQ score is considered to be the minimally clinically important difference in asthma.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Analysis population included FAS with evaluable AQLQ data at both timepoints. Missing data imputation was used to perform this analysis. Subjects with missing values were imputed as non-responders (a non-responder was defined as &lt;0.5 increase in AQLQ score at week 24)</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/80 μg</title>
            <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/160 μg</title>
            <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Change From Baseline AQLQ ≥ 0.5</title>
          <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional function and environmental stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life. An improvement of 0.5 points in AQLQ score is considered to be the minimally clinically important difference in asthma.</description>
          <population>Analysis population included FAS with evaluable AQLQ data at both timepoints. Missing data imputation was used to perform this analysis. Subjects with missing values were imputed as non-responders (a non-responder was defined as &lt;0.5 increase in AQLQ score at week 24)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="444"/>
                <count group_id="O2" value="454"/>
                <count group_id="O3" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                    <measurement group_id="O2" value="333"/>
                    <measurement group_id="O3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.108</p_value>
            <p_value_desc>P-value is one sided</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model via the GEE</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-Value is one sided</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model via the GEE</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC)</title>
        <description>FVC is the total volume of air exhaled during a expiratory maneuvre. It was assessed by performing a spirometry assessment.</description>
        <time_frame>Baseline, Week 8, Week 16 and Week 24</time_frame>
        <population>Analysis population included FAS with FVC data at the respective visit. Number analyzed signified number of participants who were evaluable for this measure at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/80 μg</title>
            <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/160 μg</title>
            <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC)</title>
          <description>FVC is the total volume of air exhaled during a expiratory maneuvre. It was assessed by performing a spirometry assessment.</description>
          <population>Analysis population included FAS with FVC data at the respective visit. Number analyzed signified number of participants who were evaluable for this measure at specified timepoints.</population>
          <units>Litre (L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="438"/>
                <count group_id="O3" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="395"/>
                    <count group_id="O3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.216" spread="0.021"/>
                    <measurement group_id="O2" value="0.272" spread="0.021"/>
                    <measurement group_id="O3" value="0.219" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.221" spread="0.021"/>
                    <measurement group_id="O2" value="0.275" spread="0.021"/>
                    <measurement group_id="O3" value="0.217" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="372"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.214" spread="0.022"/>
                    <measurement group_id="O2" value="0.280" spread="0.022"/>
                    <measurement group_id="O3" value="0.186" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.908</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.055</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.870</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.047</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.303</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.095</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.041</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity (FEF25-75)</title>
        <description>Forced expiratory flow during the mid (25 - 75%) portion of the FVC. It was assessed by performing spirometric assessment.</description>
        <time_frame>Baseline, Week 8, Week 16 and Week 24</time_frame>
        <population>Analysis population included FAS with FEF25-75 data at the respective visit. Number analyzed signified number of participants who were evaluable for this measure at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/80 μg</title>
            <description>QVM149 150/50/80 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/160 μg</title>
            <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
            <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity (FEF25-75)</title>
          <description>Forced expiratory flow during the mid (25 - 75%) portion of the FVC. It was assessed by performing spirometric assessment.</description>
          <population>Analysis population included FAS with FEF25-75 data at the respective visit. Number analyzed signified number of participants who were evaluable for this measure at specified timepoints.</population>
          <units>Litres/second (L/s)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="438"/>
                <count group_id="O3" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="395"/>
                    <count group_id="O3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.290" spread="0.027"/>
                    <measurement group_id="O2" value="0.332" spread="0.027"/>
                    <measurement group_id="O3" value="0.270" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.291" spread="0.028"/>
                    <measurement group_id="O2" value="0.355" spread="0.027"/>
                    <measurement group_id="O3" value="0.297" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="372"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.290" spread="0.028"/>
                    <measurement group_id="O2" value="0.375" spread="0.028"/>
                    <measurement group_id="O3" value="0.286" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.563</p_value>
            <p_value_desc>P-value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.048</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.844</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.062</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.097</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.927</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.067</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-Value is two-sided</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.159</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected starting on or after the time of first administration of study drug but not later than 7 days (30 days in case of a Serious Adverse Events) after the last administration, up to maximum duration of 203 days.</time_frame>
      <desc>Any sign or symptom that occurs during the study treatment but not later than 7 days (30 days in case of a Serious Adverse Events) after the last administration.&#xD;
Analysis performed on the safety set population. Safety Set consisted of all participants who received at least one dose of study medication during this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>QVM149 150/50/80 μg</title>
          <description>QVM149 150/50/80 µg o.d. delivered via Concept1</description>
        </group>
        <group group_id="E2">
          <title>QVM149 150/50/160 µg</title>
          <description>QVM149 150/50/160 μg o.d. delivered via Concept1</description>
        </group>
        <group group_id="E3">
          <title>Salmeterol/Fluticasone 50/500 μg Plus Tiotropium 5 μg</title>
          <description>Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Intentional product misuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Respiratory tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="246" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="241" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Panophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Procedural failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Atopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Perennial allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Ear infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Laryngitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Perichondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Viral tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bronchial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Exposure to allergen</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Crystal urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Red blood cells urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Mineral metabolism disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Osteoporosis postmenopausal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Respiratory tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Convulsions local</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Phantom limb syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Larynx irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Vasomotor rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Vocal cord inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

